- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 58 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
- CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
- CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities
- CytoSorbents Announces 2019 Financial and Operational Results
- CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits
- CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection
- CytoSorbents to Report Fiscal 2019 Operating and Financial Results and to Present at Cowen 40th Annual Healthcare Conference
- Coronavirus treatment developer hopes FDA will fast-track the therapy in US
-
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
What is CytoSorb?
CytoSorbents CEO Dr. Phillip Chan on The Street, discussing how CytoSorbents flagship treatment CytoSorb has been used to treat 65 patients in China as well as in Italy with COVID-19 infection.click here
- slider1.jpg
